3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2023-01-01; 120: 110641
DOI: 10.1016/j.pnpbp.2022.110641
Lire sur PubMed
1. Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jan 10;120:110641. doi:
10.1016/j.pnpbp.2022.110641. Epub 2022 Sep 17.
3-year incidence and predictors of metabolic syndrome in schizophrenia in the
national FACE-SZ cohort.
Godin O(1), Pignon B(1), Szoke A(1), Boyer L(2), Aouizerate B(3), Schorr B(4),
André M(5), Capdevielle D(5), Chereau I(6), Coulon N(7), Dassing R(4), Dubertret
C(8), Etain B(9), Leignier S(7), Llorca PM(6), Mallet J(8), Misdrahi D(10),
Passerieux C(11), Rey R(12), Urbach M(11), Schürhoff F(1), Leboyer M(1), Fond
G(13).
Author information:
(1)Fondation FondaMental, Créteil, France; Université Paris-Est Créteil, INSERM
U955, Département Hospitalo-Universitaire de Psychiatrie et d’Addictologie des
Hôpitaux Universitaires H Mondor, AP-HP, Créteil, France.
(2)Fondation FondaMental, Créteil, France; AP-HM, Aix-Marseille Univ, School of
medicine – La Timone Medical Campus, EA 3279: CEReSS – Health Service Research
and Quality of Life Center, 27 Boulevard Jean Moulin, 13005 Marseille, France.
(3)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; INRAE, NutriNeuro, University
of Bordeaux, U1286, Bordeaux F-33076, France.
(4)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(5)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm, 1061, Montpellier, France.
(6)Fondation FondaMental, Créteil, France; CHU Clermont-Ferrand, Department of
Psychiatry, University of Clermont Auvergne, EA 7280 Clermont-Ferrand, France.
(7)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(8)Fondation FondaMental, Créteil, France; Université de Paris, INSERM UMR1266,
AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, Service de Psychiatrie et
Addictologie, Hôpital Louis Mourier, Colombes, France.
(9)Fondation FondaMental, Créteil, France; Assistance Publique des Hopitaux de
Paris (AP-HP), GHU Saint-Louis – Lariboisiere – Fernand Widal, DMU
Neurosciences, Departement de Psychiatrie et de Medecine Addictologique, INSERM
UMRS 1144, Universite de Paris, Paris, France.
(10)Fondation FondaMental, Créteil, France; Department of Adult Psychiatry,
Charles Perrens Hospital, Bordeaux, France; University of Bordeaux, CNRS UMR
5287-INCIA «Neuroimagerie et Cognition Humaine», France.
(11)Fondation FondaMental, Créteil, France; Service Universitaire de psychiatrie
et d’addictologie du Centre Hospitalier de Versailles, INSERM UMR1018, CESP,
Team « DevPsy », Université de Versailles Saint-Quentin-en-Yvelines, Paris,
Saclay, France.
(12)Fondation FondaMental, Créteil, France; INSERM U1028 CNRS UMR5292, Centre de
Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe
PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678
Bron Cedex, France.
(13)Fondation FondaMental, Créteil, France; AP-HM, Aix-Marseille Univ, School of
medicine – La Timone Medical Campus, EA 3279: CEReSS – Health Service Research
and Quality of Life Center, 27 Boulevard Jean Moulin, 13005 Marseille, France.
Electronic address: .
AIMS: Metabolic Syndrome (MetS) is a major health epidemic of Western countries
and patients with schizophrenia is a particularly vulnerable population due to
lifestyle, mental illness and treatment factors. However, we lack prospective
data to guide prevention. The aim of our study is then to determine MetS
incidence and predictors in schizophrenia.
METHOD: Participants were recruited in 10 expert centers at a national level and
followed-up for 3 years. MetS was defined according to the International
Diabetes Federation criteria. Inverse probability weighting methods were used to
correct for attrition bias.
RESULTS: Among the 512 participants followed-up for 3 years, 77.9% had at least
one metabolic disturbance. 27.5% were identified with MetS at baseline and
excluded from the analyses. Among the rest of participants (N = 371, mean aged
31.2 (SD = 9.1) years, with mean illness duration of 10.0 (SD = 7.6) years and
273 (73.6%) men), MetS incidence was 20.8% at 3 years and raised to 23.6% in
tobacco smokers, 29.4% in participants receiving antidepressant prescription at
baseline and 42.0% for those with 2 disturbed metabolic disturbances at
baseline. Our multivariate analyses confirmed tobacco smoking and antidepressant
consumption as independent predictors of MetS onset (adjusted odds ratios
(aOR) = 3.82 [1.27-11.45], p = 0.016, and aOR = 3.50 [1.26-9.70], p = 0.0158).
Antidepressant prescription predicted more specifically increased lipid
disturbances and paroxetine was associated with the highest risk of MetS onset.
CONCLUSION: These results are an alarm call to prioritize MetS prevention and
research in schizophrenia. We have listed interventions that should be actively
promoted in clinical practice.
Copyright © 2022 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.pnpbp.2022.110641
PMID: 36122839 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of Competing Interest All authors
reported no biomedical financial interests or potential conflicts of interest.